Dr Sonia Friedman and colleagues analyzed the chance of a live birth, and the impact of inflammatory bowel disease surgery in women with Crohn's disease (CD) or ulcerative colitis (UC) who have undergone assisted reproductive technology treatments.
The team performed a nationwide cohort study based on the Danish health registries.
The research team compared all women with and without CD or UC who received a first time ART treatment from 1994 to 2012 with follow-up until 2013.
The team's outcome was live birth per woman within 18 months after the first assisted reproductive technology treatment.
The research team adjusted for multiple covariates and looked specifically at CD and UC surgeries before assisted reproductive technology.
|In women with UC, the adjusted odds ratio of a live birth was 0.82|
|Inflammatory Bowel Diseases|
In all, 381 women with UC, 158 women with CD, and 50,321 women without inflammatory bowel disease received first time assisted reproductive technology treatments.
In women with UC, the team found that the adjusted odds ratio of a live birth was 0.82.
In women with CD, the researchers observed that the adjusted odds ratio of a live birth was 0.58.
In women with CD having previous CD surgery versus no CD surgery, the adjusted odds ratio of a live birth was significantly decreased.
The research team noted that in women with UC with previous UC surgery, the similar odds ratio was 0.81.
Dr Friedman's team commented, "In women with CD surgery, the chance of a live birth within 18 months after initiation of assisted reproductive technology treatment was significantly decreased."
"This knowledge should help patients make decisions regarding pregnancy planning."